PLK3: Polo Like Kinase 3
A serine/threonine-protein kinase involved in cell cycle regulation, DNA damage response, and tumor suppression.
Gene Information Card
| Symbol | PLK3 |
|---|---|
| Full Name | Polo Like Kinase 3 |
| Gene Type | protein-coding |
| Chromosomal Location | 1p34.1 |
| NCBI Gene ID | 1263 ncbi.nlm.nih.gov/gene/1263 |
| Ensembl ID | ENSG00000173846 |
| UniProt ID | Q9H4B4 |
| OMIM ID | 602913 |
| HGNC ID | 9078 |
| Aliases | CNK, FNK, PRK |
Description
PLK3 (Polo Like Kinase 3) encodes a serine/threonine-protein kinase belonging to the polo-like kinase family. It plays critical roles in cell cycle progression, particularly in G2/M phase transition, and is involved in the DNA damage response. PLK3 is considered a tumor suppressor, with loss or downregulation observed in various cancers. It phosphorylates and regulates key proteins such as p53 and CHK2.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Cancer (various types) | Loss of PLK3 expression or function contributes to genomic instability and tumorigenesis. | COSMIC, NCBI Gene, PubMed |
| Hepatocellular carcinoma | Reduced PLK3 expression correlates with poor prognosis and increased proliferation. | NCBI Gene, PubMed |
| Colorectal cancer | PLK3 downregulation associated with tumor progression and metastasis. | COSMIC, PubMed |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Testis | 12.5 | Medium |
| Bone marrow | 8.3 | Low |
| Lymph node | 7.1 | Low |
| Spleen | 6.9 | Low |
| Brain | 5.2 | Not detected |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HeLa | 10.2 | Cervical cancer cell line |
| MCF7 | 7.8 | Breast cancer cell line |
| A549 | 6.5 | Lung cancer cell line |
| HEK293 | 9.1 | Embryonic kidney cell line |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1015C>T (p.Arg339Trp) | Missense | 0.02% | Unknown functional impact |
| c.1246G>A (p.Glu416Lys) | Missense | 0.01% | Potential loss of function |
| c.1432_1433insA | Frameshift | <0.01% | Loss of function |
Mutation functional classification
Loss of Function (LOF)
Frameshift and nonsense mutations in PLK3 are predicted to result in loss of kinase activity, contributing to tumorigenesis.
Gain of Function (GOF)
No confirmed gain-of-function mutations reported in PLK3.
Dominant Negative (DN)
No dominant-negative mutations described for PLK3.
View complete mutation data：
Gene Ontology (GO)
Pathways
• Cell Cycle
• Mitotic (Reactome: R-HSA-69278)
• DNA Damage Response (Reactome: R-HSA-73894)
• p53 Signaling Pathway (KEGG: hsa04115)
Protein Summary
PLK3 is a 646-amino acid serine/threonine kinase with a polo-box domain. It localizes to the nucleus and centrosomes, regulating mitotic entry and DNA damage checkpoints. PLK3 phosphorylates p53 at Ser46, promoting apoptosis in response to stress. Its expression is frequently reduced in cancers, supporting a tumor suppressor role.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PLK3 Knockout HEK293 Cell Line | EDJ-KQ1539 | Human | 1263 | Details Get a Quote |
| PLK3 Knockout HCT 116 Cell Line | EDJ-KQ21201 | Human | 1263 | Details Get a Quote |
| PLK3 Knockout HeLa Cell Line | EDJ-KQ21202 | Human | 1263 | Details Get a Quote |
| PLK3 Knockout A-549 Cell Line | EDJ-KQ19838 | Human | 1263 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
